Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 11/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 9/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.49 |
| ▸ | MBTD1 | Q05BQ5 | 4/20 | 0.48 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.48 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL521553 | 0.87 | L3MBTL3 (0.61) | L3MBTL3L3MBTL1HRH3MBTD1TP53BP1 | |
| SCHEMBL3920524 | 0.85 | L3MBTL3 (0.68) | L3MBTL3L3MBTL1HRH3MBTD1TP53BP1 | |
| SCHEMBL22345350 | 0.85 | L3MBTL3 (0.47) | L3MBTL3L3MBTL1HRH3MBTD1TP53BP1 | |
| SCHEMBL22345351 | 0.85 | L3MBTL3 (0.47) | L3MBTL3L3MBTL1HRH3MBTD1TP53BP1 | |
| SCHEMBL4385636 | 0.83 | L3MBTL3 (0.69) | L3MBTL3L3MBTL1HRH3MBTD1TP53BP1 | |
| SCHEMBL3928388 | 0.82 | L3MBTL3 (0.66) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL3926212 | 0.82 | L3MBTL3 (0.68) | L3MBTL3L3MBTL1HRH3MBTD1TP53BP1 | |
| SCHEMBL21671919 | 0.79 | MEN1 (0.64) | L3MBTL3L3MBTL1KDM4EPOLBALDH1A1 | |
| SCHEMBL1662915 | 0.79 | PHGDH (0.65) | L3MBTL1KDM4EPOLBALDH1A1 | |
| SCHEMBL1450519 | 0.77 | ALDH1A1 (0.52) | POLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260042753-A1 | INDAZOLYL-ISOXAZOLE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | MERCK PATENT GMBH (DE) | 2026-02-12 | — | — | US | disclosed |
| US-12486260-B2 | Indazolyl-isoxazole derivatives for the treatment of diseases such as cancer | MERCK PATENT GMBH (DE) | 2025-12-02 | — | — | US | disclosed |
| EP-4520326-A2 | INDAZOLYL-ISOXAZOLE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | Merck Patent GmbH (DE) | 2025-03-12 | — | — | EP | disclosed |
| EP-3924340-B1 | INDAZOLYL-ISOXAZOLE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | MERCK PATENT GMBH (DE) | 2025-01-29 | — | — | EP | disclosed |
| CN-118955486-A | Indazolyl-isoxazole derivatives for the treatment of diseases such as cancer | 默克专利股份公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-113474334-B | Indazolyl-isoxazole derivatives for the treatment of diseases such as cancer | 默克专利股份公司 | 2024-08-06 | — | — | CN | disclosed |
| US-20220127254-A1 | INDAZOLYL-ISOXAZOLE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | MERCK PATENT GMBH (DE) | 2022-04-28 | — | — | US | disclosed |
| US-20220127254-A1 | INDAZOLYL-ISOXAZOLE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | MERCK PATENT GMBH (DE) | 2022-04-28 | — | — | US | disclosed |
| EP-3924340-A1 | INDAZOLYL-ISOXAZOLE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | Merck Patent GmbH (DE) | 2021-12-22 | — | — | EP | disclosed |
| CN-113474334-A | Indazolyl-isoxazole derivatives for the treatment of diseases such as cancer | 默克专利股份公司 | 2021-10-01 | — | — | CN | disclosed |
| WO-2020165062-A1 | INDAZOLYL-ISOXAZOLE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | MERCK PATENT GMBH (DE) | 2020-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260042753-A1 | INDAZOLYL-ISOXAZOLE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | KIT, ABL1, DSTYK | L3MBTL3 2711/4885L3MBTL1 3490/4885HRH3 2489/4885 |
| US-12486260-B2 | Indazolyl-isoxazole derivatives for the treatment of diseases such as cancer | KIT, TNNI3K, CILK1 | L3MBTL3 4007/4885L3MBTL1 3815/4885HRH3 899/4885 |
| US-20220127254-A1 | INDAZOLYL-ISOXAZOLE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS CANCER | KIT, TNNI3K, CILK1 | L3MBTL3 4007/4885L3MBTL1 3815/4885HRH3 899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.